Comparison of somatostatin and cimetidine in the treatment of acute bleeding esophageal varices

P. A. Testoni, E. Masci, S. Passaretti

Research output: Contribution to journalArticle

Abstract

Little and conflicting data are reported in the literature on the efficacy of somatostatin in the treatment of acute bleeding of esophageal varices in patients with portal hypertension due to hepatic cirrhosis. In this study the effectiveness of somatostatin has been evaluated in two groups of patients, one group with profuse and the other group with moderate bleeding (with and without Sengstaken-Blakemore tube). The overall rate of success in the two groups is similar, but the mean bleeding period has been significantly reduced in the somatostatin group (15 patients) in comparison with the cimetidine group (14 patients), both in cases without Sengstaken-Blakemore intubation and in severe cases in which local tamponade was required. Somatostatin also markedly reduced the period of intubation. This study confirms that somatostatin may be used as a safe, first choice therapy in the medical management of acute variceal hemorrhage.

Original languageEnglish
Pages (from-to)758-766
Number of pages9
JournalCurrent Therapeutic Research
Volume39
Issue number5
Publication statusPublished - 1986

Fingerprint

Esophageal and Gastric Varices
Cimetidine
Somatostatin
Hemorrhage
Intubation
Therapeutics
Portal Hypertension
Liver Cirrhosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparison of somatostatin and cimetidine in the treatment of acute bleeding esophageal varices. / Testoni, P. A.; Masci, E.; Passaretti, S.

In: Current Therapeutic Research, Vol. 39, No. 5, 1986, p. 758-766.

Research output: Contribution to journalArticle

@article{4d57033ffd804148878dffef5b17b13c,
title = "Comparison of somatostatin and cimetidine in the treatment of acute bleeding esophageal varices",
abstract = "Little and conflicting data are reported in the literature on the efficacy of somatostatin in the treatment of acute bleeding of esophageal varices in patients with portal hypertension due to hepatic cirrhosis. In this study the effectiveness of somatostatin has been evaluated in two groups of patients, one group with profuse and the other group with moderate bleeding (with and without Sengstaken-Blakemore tube). The overall rate of success in the two groups is similar, but the mean bleeding period has been significantly reduced in the somatostatin group (15 patients) in comparison with the cimetidine group (14 patients), both in cases without Sengstaken-Blakemore intubation and in severe cases in which local tamponade was required. Somatostatin also markedly reduced the period of intubation. This study confirms that somatostatin may be used as a safe, first choice therapy in the medical management of acute variceal hemorrhage.",
author = "Testoni, {P. A.} and E. Masci and S. Passaretti",
year = "1986",
language = "English",
volume = "39",
pages = "758--766",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Comparison of somatostatin and cimetidine in the treatment of acute bleeding esophageal varices

AU - Testoni, P. A.

AU - Masci, E.

AU - Passaretti, S.

PY - 1986

Y1 - 1986

N2 - Little and conflicting data are reported in the literature on the efficacy of somatostatin in the treatment of acute bleeding of esophageal varices in patients with portal hypertension due to hepatic cirrhosis. In this study the effectiveness of somatostatin has been evaluated in two groups of patients, one group with profuse and the other group with moderate bleeding (with and without Sengstaken-Blakemore tube). The overall rate of success in the two groups is similar, but the mean bleeding period has been significantly reduced in the somatostatin group (15 patients) in comparison with the cimetidine group (14 patients), both in cases without Sengstaken-Blakemore intubation and in severe cases in which local tamponade was required. Somatostatin also markedly reduced the period of intubation. This study confirms that somatostatin may be used as a safe, first choice therapy in the medical management of acute variceal hemorrhage.

AB - Little and conflicting data are reported in the literature on the efficacy of somatostatin in the treatment of acute bleeding of esophageal varices in patients with portal hypertension due to hepatic cirrhosis. In this study the effectiveness of somatostatin has been evaluated in two groups of patients, one group with profuse and the other group with moderate bleeding (with and without Sengstaken-Blakemore tube). The overall rate of success in the two groups is similar, but the mean bleeding period has been significantly reduced in the somatostatin group (15 patients) in comparison with the cimetidine group (14 patients), both in cases without Sengstaken-Blakemore intubation and in severe cases in which local tamponade was required. Somatostatin also markedly reduced the period of intubation. This study confirms that somatostatin may be used as a safe, first choice therapy in the medical management of acute variceal hemorrhage.

UR - http://www.scopus.com/inward/record.url?scp=0022897769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022897769&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0022897769

VL - 39

SP - 758

EP - 766

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -